Agios will receive a total of $1.1 billion in milestone payments following the FDA approval of vorasidenib
– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – –...
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key...
The company plans to submit a marketing application for mitapivat in alpha- or beta- thalassemia patients, regardless of transfusion needs, to the U.S. health regulator by the end of this year.
“ Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session “ “ Additional Presentations to Highlight Quality of Life Data from...
“ Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 “ “ Announced Positive Results from the...
Agios Pharmaceuticals said Monday that its pill Pyrukynd increased levels of hemoglobin in more sickle cell disease patients than placebo, and it plans to start a Phase III trial later this year.
New drug approvals were fewer in number in 2022. Is this a trend that will continue into 2023 or is the drop off just a cyclical anomaly?
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition